论文部分内容阅读
目的探讨舒血宁治疗急性脑梗死(AIS)的临床疗效及对患者神经功能恢复的影响。方法 100例AIS患者随机分为治疗组和对照组。对照组给予基础治疗,治疗组采用基础治联合舒血宁治疗,治疗2周后评价临床疗效,评价患者的神经功能恢复情况。结果治疗组临床疗效总有效率为86.0%,显著高于对照组(54.0%),差异有统计学意义(-6.392,P﹤0.01);治疗前两组NIHSS评分比较差异无统计学意义(t=3.569,P﹥0.05);治疗后,治疗组NIHSS评分显著下降,与对照组比较差异均有统计学意义(t=7.064,P﹤0.00);两均无明显不良反应。结论舒血宁治疗AIS能有效地提高治疗效果和改善患者的神经功能损伤,且安全可靠,值得临床推广应用。
Objective To investigate the clinical efficacy of Shuxuening in the treatment of acute cerebral infarction (AIS) and its effect on the recovery of neurological function. Methods One hundred patients with AIS were randomly divided into treatment group and control group. The control group was given basic treatment. The treatment group was treated with basic therapy combined with Shuxuening. After 2 weeks of treatment, the clinical efficacy was evaluated and the neurological recovery of the patients was evaluated. Results The total effective rate in the treatment group was 86.0%, significantly higher than that in the control group (54.0%), the difference was statistically significant (-6.392, P <0.01). There was no significant difference in NIHSS score between the two groups = 3.569, P> 0.05). After treatment, the NIHSS score of the treatment group decreased significantly compared with that of the control group (t = 7.064, P <0.00). No significant adverse reactions were found in both groups. Conclusion Shuxuening treatment of AIS can effectively improve the therapeutic effect and improve patients with neurological damage, and safe and reliable, it is worthy of clinical application.